Clinical trials: Glaucoma
Glaucoma
Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow
A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed…
- Trial name
- NCT00811850
- Testing
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension
Subjects are dosed twice daily at 9AM and 9PM for 12 weeks. The primary efficacy variable is the mean change in Intraocular Pressure (IOP) from baseline to 12 weeks.
- Trial name
- NCT01111890
- Testing
- Azarga (brinzolamide 1% / timolol 0.5%), Cosopt (dorzolamide 2% / timolol 0.5%)
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Alcon Research
Open-angle Glaucoma
Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma
This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.
- Trial name
- NCT03488550
- Testing
- ANX007
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Annexon, Inc.
Open Angle Glaucoma, Ocular Hypertension
24-hour Efficacy of AR-12286
An open-label, non-comparative, pilot evaluation of the 24-hour ocular hypotensive efficacy of AR-12286 in patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT01330979
- Testing
- AR-12286 0.5% Ophthalmic Solution
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Ocular Hypertension
A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects
A Single Centre, Placebo-Controlled, Double-Masked, Sequential Designed Study to Evaluate 3 Ophthalmic Formulations of AMA0076 in Healthy Subjects
- Conditions
- Glaucoma, Ocular Hypertension, Eye Disease
- Trial name
- NCT02003547
- Testing
- AMA0076
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Amakem, NV
Primary Open Angle Glaucoma or Ocular Hypertension
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
- Trial name
- NCT03233308
- Testing
- Netarsudil Ophthalmic Solution 0.02%
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aerie Pharmaceuticals
Open-angle Glaucoma, Ocular Hypertension
A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension
The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a…
- Trial name
- NCT03822559
- Testing
- A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL, A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
- Where
- 2 sites in China
- Volunteers
- 219 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Ocular Hypertension, Open-angle Glaucoma
Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study was to describe the safety and IOP-lowering efficacy of Travoprost New Formulations compared to TRAVATAN® and to vehicle in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00670033
- Testing
- Travoprost ophthalmic solution (new formulation), Travoprost ophthalmic solution, 0.004%, Vehicle
- Volunteers
- 158 people
- Sponsor
- Alcon Research
Ocular Hypertension, Open-angle Glaucoma
Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies
The purpose of this study is to compare the efficacy and safety of the preservative-free fixed tafluprost-timolol combination to those of tafluprost and timolol alone.
- Trial name
- NCT01292460
- Where
- 2 sites in Finland
- Volunteers
- 600 people
- Sponsor
- Santen Oy
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01217606
- Testing
- bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
- Where
- Brazil
- Volunteers
- 185 people
- Sponsor
- Allergan
Glaucoma, Open Angle or Ocular Hypertension
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM
- Trial name
- NCT03896633
- Testing
- brinzolamide 1% ophthalmic suspension, Azopt 1%
- Where
- United States
- Volunteers
- 637 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Ocular Hypertension
Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension
This study evaluates the safety and efficacy of once-daily bimatoprost 0.03% and 0.01% ophthalmic solutions compared with once-daily administered bimatoprost vehicle ophthalmic solution for 2 weeks in ethnically Japanese patients…
- Trial name
- NCT00651859
- Testing
- Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects
Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive therapy to Xalatan in subjects with glaucoma or ocular hypertension.
- Trial name
- NCT00735449
- Testing
- Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%, timolol maleate 0.5%, latanoprost 0.005%
- Where
- 2 sites in United States, Canada
- Volunteers
- 204 people
- Sponsor
- Allergan
Open-Angle Glaucoma, Ocular Hypertension
Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study in patients with POAG or OHT that will collect data on the use of Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) in a routine clinical setting.
- Trial name
- NCT01568008
- Testing
- Bimatoprost 0.01% ophthalmic solution
- Where
- Belgium
- Volunteers
- 933 people
- Sponsor
- Allergan
Open-Angle Glaucoma, Ocular Hypertension
A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study is a retrospective chart review to assess the tolerability and efficacy of treatment with Simbrinza™ used for patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02348476
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea
This study is a Post-Marketing Surveillance study to evaluate the safety and efficacy of bimatoprost/timolol (Ganfort®) Ophthalmic Solution to treat open-angle glaucoma or ocular hypertension in Korea.
- Trial name
- NCT01976624
- Testing
- bimatoprost/timolol
- Where
- South Korea
- Volunteers
- 756 people
- Sponsor
- Allergan
Ocular Hypertension, Open Angle Glaucoma
CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT04360174
- Testing
- OTX-TIC
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Ocular Therapeutix, Inc.
Cataract, Glaucoma
High Frequency Deep Sclerotomy (HFDS) ab Interno a Combination Surgical Intervention Using Cataract Surgery to Lower IOP
Objective: To compare intraocular pressure lowering effect of combined sclerotomy ab interno with phacoemulsification and phacoemulsification alone, in primary or secondary open angle glaucoma patients.
- Conditions
- Cataract, Glaucoma, POAG
- Trial name
- HFDS_abinterno (NCT02312362)
- Testing
- Combined sclerotomy ab interno and phaco, Phacoemulsification with IOL implantation
- Where
- 5 sites in Egypt, Germany and 2 more
- Volunteers
- 108 people
- Sponsor
- Oertli Instrumente AG
Glaucoma, Open-Angle, Ocular Hypertension
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients.
- Trial name
- NCT00934089
- Testing
- PF-04217329, latanoprost vehicle, latanoprost
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Primary Open Angle Glaucoma
Safety and Efficacy Study of the Hydrus Aqueous Implant in Subjects With POAG
The purpose of this study is to evaluate the ocular hypotensive effect of the Hydrus Aqueous Implant (Standard and Low-Profile), as determined by the change in IOP from baseline (preoperative) and change in the number of glaucoma…
- Trial name
- POAG (NCT03065036)
- Testing
- prestudy topical glaucoma medications
- Where
- 5 sites in Austria, Germany and 1 more
- Volunteers
- 120 people
- Sponsor
- Ivantis, Inc.